Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks

B. Cohen, Stanley; Emery, Paul; W. Greenwald, Maria; Dougados, Maxime; A. Furie, Richard; C. Genovese, Mark; C. Keystone, Edward; E. Loveless, James; Burmester, Gerd‐Rüdiger; W. Cravets, Matthew; W. Hessey, Eva; Shaw, Timothy; C. Totoritis, Mark

doi:10.1002/art.22025

Public

Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks

Shared by NobleBlocks on Aug 28, 2006 • 12:00 AM UTC

Authors:

Stanley B. Cohen

Paul Emery

Maria W. Greenwald

Abstract

Abstract Objective To determine the efficacy and safety of treatment with rituximab plus methotrexate (MTX) in patients with active rheumatoid arthritis (RA) who had an inadequate response to anti–tumor necrosis factor (anti‐TNF) therapies and to explore the pharmacokinetics and pharmacodynamics of ...

Discussions